









Markets
/
Stocks
/
nasdaq-dmac
/

DiaMedica Therapeutics Inc

DMAC

6.148USD

-0.242-3.79%

Market hours （ET）Quotes delayed by 15 min

264.81MMarket Cap

LossP/E TTM



DiaMedica Therapeutics Inc

6.148

-0.242-3.79%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of DiaMedica Therapeutics Inc

Currency: USD Updated: 2025-11-11

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

DiaMedica Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

159 / 407

Overall Ranking

289 / 4608

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

12.333

Target Price

+103.52%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

DiaMedica Therapeutics Inc Highlights

StrengthsRisks

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -9.21, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 16.92M shares, increasing 19.95% quarter-over-quarter.

Held by Leon Cooperman

Star Investor Leon Cooperman holds 3.27M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 1.96.

Financial Health

Currency: USD Updated: 2025-11-11

The company's current financial score is 5.46, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.46

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.46

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

DiaMedica Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-11

The company’s current valuation score is 6.22, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -9.21, which is -72.28% below the recent high of -2.55 and -26.46% above the recent low of -11.65.

Score

Industry at a Glance

Previous score

6.22

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 159/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-11

The company’s current earnings forecast score is 8.00, which is equal to the Biotechnology & Medical Research industry's average of 8.00. The average price target for DiaMedica Therapeutics Inc is 12.00, with a high of 14.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

12.333

Target Price

+93.01%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

522

Total

Median

Average

Company name

Ratings

Analysts

DiaMedica Therapeutics Inc

DMAC

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

...

105

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-11

The company’s current price momentum score is 7.32, which is higher than the Biotechnology & Medical Research industry's average of 6.78. Sideways: Currently, the stock price is trading between the resistance level at 7.15 and the support level at 5.71, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.92

Change

0.4

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.171

Sell

RSI(14)

45.235

Neutral

STOCH(KDJ)(9,3,3)

28.973

Buy

ATR(14)

0.343

High Vlolatility

CCI(14)

-98.821

Neutral

Williams %R

57.184

Sell

TRIX(12,20)

-0.236

Sell

StochRSI(14)

89.536

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

6.248

Sell

MA10

6.550

Sell

MA20

6.661

Sell

MA50

6.757

Sell

MA100

5.725

Buy

MA200

5.221

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-11

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.13. The latest institutional shareholding proportion is 32.74%, representing a quarter-over-quarter decrease of 45.13%. The largest institutional shareholder is Leon Cooperman, holding a total of 3.27M shares, representing 6.33% of shares outstanding, with 66.68% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

EQT Partners AB

8.38M

+51.70%

Trill AB,LLC.

7.76M

+14.78%

Jacinto (Richard II)

4.96M

+8.77%

Omega Advisors, Inc.

Star Investors

1.65M

+1.54%

B. Riley Asset Management, LLC

2.21M

BlackRock Institutional Trust Company, N.A.

1.06M

+941.19%

The Vanguard Group, Inc.

Star Investors

1.54M

+13.58%

Paragon JV Partners, LLC

650.00K

+8.33%

Geode Capital Management, L.L.C.

630.15K

+99.58%

First Manhattan Co. LLC

606.43K

Risk Assessment

Currency: USD Updated: 2025-11-11

The company’s current risk assessment score is 3.10, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.36. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.